Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
This is an open-label phase III study of regorafenib in patients with metastatic colorectal cancer (mCRC) who have progressed after all approved standard therapy. The purpose of this study is to provide additional information about the safety profile of Regorafenib.
Colorectal Neoplasms
DRUG: Regorafenib (Stivarga, BAY73- 4506)
Number of participants with adverse events as a measure of safety and tolerability, Up to 6 months|Number of participants with adverse events which caused withdrawal, dose reduction, interruption or discontinuation, Up to 6 months|Number of death, Up to 6 months|Number of participants with serious adverse events as a measure of safety and tolerability, Up to 6 months|Progression-Free Survival (PFS), The PFS is defined as the time from date of treatment assignment (i.e., date of first treatment) to date of first observed disease progression or death due to any cause, if death occurs while the subject is in the study (that is, by the last visit including during the safety follow-up visit date), and before progression is observed., Up to 6 months
This is an open-label phase III study of regorafenib in patients with metastatic colorectal cancer (mCRC) who have progressed after all approved standard therapy. The purpose of this study is to provide additional information about the safety profile of Regorafenib.